drugset / Trial / NCT00023764
Bortezomib in Treating Patients With Lymphoproliferative Disorders
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of bortezomib in treating patients who have low-grade lymphoproliferative disorders. Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth.
Timeline
- Start
- 2001-06
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 1.8 mg/m2 | Intravenous |